| 8.65 -0.5 (-5.46%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.34 | 1-year : | 12.2 |
| Resists | First : | 9.71 | Second : | 10.44 |
| Pivot price | 9 |
|||
| Supports | First : | 8.52 | Second : | 7.08 |
| MAs | MA(5) : | 8.86 |
MA(20) : | 9.06 |
| MA(100) : | 8.86  |
MA(250) : | 6.85 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 24.2 |
D(3) : | 24.7 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 11.65 | Low : | 4.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VIR ] has closed above bottom band by 20.6%. Bollinger Bands are 36.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.2 - 9.25 | 9.25 - 9.3 |
| Low: | 8.51 - 8.57 | 8.57 - 8.62 |
| Close: | 8.57 - 8.66 | 8.66 - 8.74 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Sat, 06 Jun 2026
Earnings call transcript: Vir Biotech reports larger-than-expected Q1 2026 loss - Investing.com
Thu, 04 Jun 2026
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Wed, 03 Jun 2026
Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $21.00 - MarketBeat
Tue, 02 Jun 2026
Insider Sell: Janet Napolitano Sells 3,200 Shares of Vir Biotech - GuruFocus
Tue, 02 Jun 2026
Vir Biotechnology director Janet Napolitano sells $30,239 in stock - Investing.com
Tue, 02 Jun 2026
Vir Biotechnology (VIR) director Napolitano sells 3,200 shares under 10b5-1 plan - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 169 (M) |
| Held by Insiders | 1.2881e+008 (%) |
| Held by Institutions | 6.5 (%) |
| Shares Short | 16,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.5105e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 459 % |
| Return on Assets (ttm) | 241.3 % |
| Return on Equity (ttm) | -24.8 % |
| Qtrly Rev. Growth | 6.55e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -28.06 |
| EBITDA (p.s.) | -2.18353e+008 |
| Qtrly Earnings Growth | -3.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -446 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.31 |
| Price to Cash Flow | 2.67 |
| Dividend | 0 |
| Forward Dividend | 1.683e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|